TY - JOUR
T1 - Plasma Androgen Receptor and Docetaxel for Metastatic Castration-resistant Prostate Cancer
AU - Conteduca, Vincenza
AU - Jayaram, Anuradha
AU - Romero-Laorden, Nuria
AU - Wetterskog, Daniel
AU - Salvi, Samanta
AU - Gurioli, Giorgia
AU - Scarpi, Emanuela
AU - Castro, Elena
AU - Marin-Aguilera, Mercedes
AU - Lolli, Cristian
AU - Schepisi, Giuseppe
AU - Maugeri, Antonio
AU - Wingate, Anna
AU - Farolfi, Alberto
AU - Casadio, Valentina
AU - Medina, Ana
AU - Puente, Javier
AU - Vidal, Mª José Méndez
AU - Morales-Barrera, Rafael
AU - Villa-Guzmán, Jose C.
AU - Hernando, Susana
AU - Rodriguez-Vida, Alejo
AU - González-del-Alba, Aránzazu
AU - Mellado, Begoña
AU - Gonzalez-Billalabeitia, Enrique
AU - Olmos, David
AU - Attard, Gerhardt
AU - De Giorgi, Ugo
PY - 2019/3
Y1 - 2019/3
N2 - Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.
AB - Analysis of metastatic castration-resistant prostate cancer (mCRPC) patients receiving first-line therapy showed that plasma androgen receptor (AR)-normal status favored treatment with abiraterone or enzalutamide, whilst docetaxel benefit was unrelated to plasma AR. AR testing in plasma may have clinical utility for treatment selection in mCRPC.
KW - Androgen receptor
KW - Androgen receptor–directed therapies
KW - Biomarker
KW - Castration-resistant prostate cancer
KW - Docetaxel
KW - Plasma DNA
UR - http://www.scopus.com/inward/record.url?scp=85055497223&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85055497223&partnerID=8YFLogxK
U2 - 10.1016/j.eururo.2018.09.049
DO - 10.1016/j.eururo.2018.09.049
M3 - Article
C2 - 30773204
AN - SCOPUS:85055497223
VL - 75
SP - 368
EP - 373
JO - European Urology
JF - European Urology
SN - 0302-2838
IS - 3
ER -